期刊
CURRENT RHEUMATOLOGY REPORTS
卷 14, 期 5, 页码 472-480出版社
SPRINGER
DOI: 10.1007/s11926-012-0275-1
关键词
Rheumatoid arthritis; Early treatment; Prevention; Treatment; Strategies; Management; Therapy; DMARD; Joint damage; Autoimmunity
类别
资金
- NIH [T32AR07534, U19AI50864]
- Artritis Foundation
- American College of Rheumatology
- Abbott Laboratories, Inc.
- Walter S. and Lucienne Driskill Foundation
Data now suggest that current strategies in the treatment of rheumatoid arthritis (RA) should focus on early identification and diagnosis, followed by early initiation of DMARD therapy. Initiation of treatment in early RA-ideally, less than 3-6 months after symptom onset-improves the success of achieving disease remission and reduces joint damage and disability. While the optimal treatment regimen in early RA is unclear, use of initial DMARD mono-or combination therapy with prompt escalation to achieve low disease activity or remission is an appropriate approach. Ultimately, the goal of RA management should be the prevention of inflammatory joint disease and, thereby, prevention of disability. To date, studies have shown that pharmacologic interventions can delay progression from undifferentiated inflammatory arthritis to classifiable RA. However, further investigation is needed to identify asymptomatic individuals at high risk for future RA and to intervene early enough in the pathogenesis of RA to prevent progression to clinical disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据